P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival

P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival

Abstract Background 20-30% of breast cancer patients develop brain metastases (BM) and 5% leptomeningeal metastases (LM). Incidence of BM and/or LM is dependent on breast cancer subtype. Treatment of BM consists of local treatment (resection and/or radiotherapy) and if possible systemic therapy. LM...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2022-09, Vol.24 (Supplement_2), p.ii72-ii72
Hauptverfasser: Luitse, M J A, Boles, G, Sonke, G S, Brandsma, D
Format: Artikel
Sprache:eng
Schlagworte:
POSTER PRESENTATIONS
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page ii72
container_issue Supplement_2
container_start_page ii72
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 24
creator Luitse, M J A
Boles, G
Sonke, G S
Brandsma, D
description Abstract Background 20-30% of breast cancer patients develop brain metastases (BM) and 5% leptomeningeal metastases (LM). Incidence of BM and/or LM is dependent on breast cancer subtype. Treatment of BM consists of local treatment (resection and/or radiotherapy) and if possible systemic therapy. LM can be treated with radiotherapy of the symptomatic location of the nervous system and/or systemic therapy. Capecitabin is effective for both systemic metastases and BM of HER2-positive breast cancer. The effect of capecitabine in the non-HER2-positive breast cancers and in the LM group is largely unknown. The goal of this study is to determine the intracranial response of capecitabine and survival in HM and/or LM of the various breast cancer subtypes. Material and Methods breast cancer patients with HM and/or LM treated with capecitabine were selected retrospectively from a breast cancer patient cohort treated at the Netherlands Cancer Institute - Antoni van Leeuwenhoek between 2005 and 2020. Follow-up MRI scans of the brains were performed in all patients. The primary endpoints were intracranial response, intracranial progression-free survival (PFS) and overall survival (OS). Subgroup analyses for breast cancer subtypes and BM and LM patient groups were done. Results 93 of 381 patients treated for CNS metastases of breast cancer fulfilled the inclusion criteria. Sixty-one patients (66%) had HM only, 13 (14%) had LM only and 19 patients (20%) had both HM and LM. Forty-six percent of patients had HER2-positive breast cancer, 26% had hormone receptor-positive breast cancer and 28% of patients had a triple negative subtype. After three months of capecitabine treatment intracranial response was 53%. Median OS in the patient group with intracranial response was 16.5 months versus 4.5 months in the non-response group. The hazard ratio (HR) for the median OS, corrected for radiotherapy and concurrently administered, other systemic therapy was 0.33 (95% CI: 0.17-0.67). Median intracranial PFS was 7.3 months in the response group versus 1.4 months in the non-response group (p
doi_str_mv 10.1093/neuonc/noac174.250
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9443387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noac174.250</oup_id><sourcerecordid>10.1093/neuonc/noac174.250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1800-458db9b1c21b9082a44c4d1df2470ca7808045694af54160fe9e1e696bff16ed3</originalsourceid><addsrcrecordid>eNqNkN1KxDAQhYsouK6-gFd5ga6ZNk1bLwRd_INFBfU6TNOJW2mTkrQLvr1ddxG8EwZmYM45HL4oOge-AF6mF5ZGZ_WFdaghF4sk4wfRDLIkjbNCysOfO4mLDPLj6CSET84TyCTMovULwELC4oYtsSfdDFg1ltjgCYeO7MCcYcunV9bRgGEaCsx417FqEoSBabSa_CVr7OBRe7QNtsxT6J0NxNDWLIx-02ywPY2ODLaBzvZ7Hr3f3b4tH-LV8_3j8noVayg4j0VW1FVZgU6gKnmRoBBa1FCbRORcY17wgotMlgJNJkByQyUByVJWxoCkOp1HV7vcfqw6qjVtm7Wq902H_ks5bNTfj23W6sNtVClEmhb5FJDsArR3IXgyv17gagtb7WCrPWw1wZ5M8c7kxv4_-m_BnobW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><creator>Luitse, M J A ; Boles, G ; Sonke, G S ; Brandsma, D</creator><creatorcontrib>Luitse, M J A ; Boles, G ; Sonke, G S ; Brandsma, D</creatorcontrib><description>Abstract Background 20-30% of breast cancer patients develop brain metastases (BM) and 5% leptomeningeal metastases (LM). Incidence of BM and/or LM is dependent on breast cancer subtype. Treatment of BM consists of local treatment (resection and/or radiotherapy) and if possible systemic therapy. LM can be treated with radiotherapy of the symptomatic location of the nervous system and/or systemic therapy. Capecitabin is effective for both systemic metastases and BM of HER2-positive breast cancer. The effect of capecitabine in the non-HER2-positive breast cancers and in the LM group is largely unknown. The goal of this study is to determine the intracranial response of capecitabine and survival in HM and/or LM of the various breast cancer subtypes. Material and Methods breast cancer patients with HM and/or LM treated with capecitabine were selected retrospectively from a breast cancer patient cohort treated at the Netherlands Cancer Institute - Antoni van Leeuwenhoek between 2005 and 2020. Follow-up MRI scans of the brains were performed in all patients. The primary endpoints were intracranial response, intracranial progression-free survival (PFS) and overall survival (OS). Subgroup analyses for breast cancer subtypes and BM and LM patient groups were done. Results 93 of 381 patients treated for CNS metastases of breast cancer fulfilled the inclusion criteria. Sixty-one patients (66%) had HM only, 13 (14%) had LM only and 19 patients (20%) had both HM and LM. Forty-six percent of patients had HER2-positive breast cancer, 26% had hormone receptor-positive breast cancer and 28% of patients had a triple negative subtype. After three months of capecitabine treatment intracranial response was 53%. Median OS in the patient group with intracranial response was 16.5 months versus 4.5 months in the non-response group. The hazard ratio (HR) for the median OS, corrected for radiotherapy and concurrently administered, other systemic therapy was 0.33 (95% CI: 0.17-0.67). Median intracranial PFS was 7.3 months in the response group versus 1.4 months in the non-response group (p&lt;0.001).The corrected HR for median intracranial PFS 0.13 (95% CI 0.06-0.27). The HER2-positive subtype group showed the longest median OS (22 months) as compared to the other subtypes (OS in hormone-receptor positive and triple negative subtype both 12 months) Conclusion Fifty-three percent of breast cancer patients with HM and/or LM treated with capecitabine demonstrate an intracranial response after three months of treatment. HER2+ breast cancer patients with HM and/or LM have a longer survival than patients with hormone receptor-positive or triple negative breast cancer subtypes.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noac174.250</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>POSTER PRESENTATIONS</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2022-09, Vol.24 (Supplement_2), p.ii72-ii72</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443387/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443387/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Luitse, M J A</creatorcontrib><creatorcontrib>Boles, G</creatorcontrib><creatorcontrib>Sonke, G S</creatorcontrib><creatorcontrib>Brandsma, D</creatorcontrib><title>P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract Background 20-30% of breast cancer patients develop brain metastases (BM) and 5% leptomeningeal metastases (LM). Incidence of BM and/or LM is dependent on breast cancer subtype. Treatment of BM consists of local treatment (resection and/or radiotherapy) and if possible systemic therapy. LM can be treated with radiotherapy of the symptomatic location of the nervous system and/or systemic therapy. Capecitabin is effective for both systemic metastases and BM of HER2-positive breast cancer. The effect of capecitabine in the non-HER2-positive breast cancers and in the LM group is largely unknown. The goal of this study is to determine the intracranial response of capecitabine and survival in HM and/or LM of the various breast cancer subtypes. Material and Methods breast cancer patients with HM and/or LM treated with capecitabine were selected retrospectively from a breast cancer patient cohort treated at the Netherlands Cancer Institute - Antoni van Leeuwenhoek between 2005 and 2020. Follow-up MRI scans of the brains were performed in all patients. The primary endpoints were intracranial response, intracranial progression-free survival (PFS) and overall survival (OS). Subgroup analyses for breast cancer subtypes and BM and LM patient groups were done. Results 93 of 381 patients treated for CNS metastases of breast cancer fulfilled the inclusion criteria. Sixty-one patients (66%) had HM only, 13 (14%) had LM only and 19 patients (20%) had both HM and LM. Forty-six percent of patients had HER2-positive breast cancer, 26% had hormone receptor-positive breast cancer and 28% of patients had a triple negative subtype. After three months of capecitabine treatment intracranial response was 53%. Median OS in the patient group with intracranial response was 16.5 months versus 4.5 months in the non-response group. The hazard ratio (HR) for the median OS, corrected for radiotherapy and concurrently administered, other systemic therapy was 0.33 (95% CI: 0.17-0.67). Median intracranial PFS was 7.3 months in the response group versus 1.4 months in the non-response group (p&lt;0.001).The corrected HR for median intracranial PFS 0.13 (95% CI 0.06-0.27). The HER2-positive subtype group showed the longest median OS (22 months) as compared to the other subtypes (OS in hormone-receptor positive and triple negative subtype both 12 months) Conclusion Fifty-three percent of breast cancer patients with HM and/or LM treated with capecitabine demonstrate an intracranial response after three months of treatment. HER2+ breast cancer patients with HM and/or LM have a longer survival than patients with hormone receptor-positive or triple negative breast cancer subtypes.</description><subject>POSTER PRESENTATIONS</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNkN1KxDAQhYsouK6-gFd5ga6ZNk1bLwRd_INFBfU6TNOJW2mTkrQLvr1ddxG8EwZmYM45HL4oOge-AF6mF5ZGZ_WFdaghF4sk4wfRDLIkjbNCysOfO4mLDPLj6CSET84TyCTMovULwELC4oYtsSfdDFg1ltjgCYeO7MCcYcunV9bRgGEaCsx417FqEoSBabSa_CVr7OBRe7QNtsxT6J0NxNDWLIx-02ywPY2ODLaBzvZ7Hr3f3b4tH-LV8_3j8noVayg4j0VW1FVZgU6gKnmRoBBa1FCbRORcY17wgotMlgJNJkByQyUByVJWxoCkOp1HV7vcfqw6qjVtm7Wq902H_ks5bNTfj23W6sNtVClEmhb5FJDsArR3IXgyv17gagtb7WCrPWw1wZ5M8c7kxv4_-m_BnobW</recordid><startdate>20220905</startdate><enddate>20220905</enddate><creator>Luitse, M J A</creator><creator>Boles, G</creator><creator>Sonke, G S</creator><creator>Brandsma, D</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20220905</creationdate><title>P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival</title><author>Luitse, M J A ; Boles, G ; Sonke, G S ; Brandsma, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1800-458db9b1c21b9082a44c4d1df2470ca7808045694af54160fe9e1e696bff16ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>POSTER PRESENTATIONS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luitse, M J A</creatorcontrib><creatorcontrib>Boles, G</creatorcontrib><creatorcontrib>Sonke, G S</creatorcontrib><creatorcontrib>Brandsma, D</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luitse, M J A</au><au>Boles, G</au><au>Sonke, G S</au><au>Brandsma, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2022-09-05</date><risdate>2022</risdate><volume>24</volume><issue>Supplement_2</issue><spage>ii72</spage><epage>ii72</epage><pages>ii72-ii72</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract Background 20-30% of breast cancer patients develop brain metastases (BM) and 5% leptomeningeal metastases (LM). Incidence of BM and/or LM is dependent on breast cancer subtype. Treatment of BM consists of local treatment (resection and/or radiotherapy) and if possible systemic therapy. LM can be treated with radiotherapy of the symptomatic location of the nervous system and/or systemic therapy. Capecitabin is effective for both systemic metastases and BM of HER2-positive breast cancer. The effect of capecitabine in the non-HER2-positive breast cancers and in the LM group is largely unknown. The goal of this study is to determine the intracranial response of capecitabine and survival in HM and/or LM of the various breast cancer subtypes. Material and Methods breast cancer patients with HM and/or LM treated with capecitabine were selected retrospectively from a breast cancer patient cohort treated at the Netherlands Cancer Institute - Antoni van Leeuwenhoek between 2005 and 2020. Follow-up MRI scans of the brains were performed in all patients. The primary endpoints were intracranial response, intracranial progression-free survival (PFS) and overall survival (OS). Subgroup analyses for breast cancer subtypes and BM and LM patient groups were done. Results 93 of 381 patients treated for CNS metastases of breast cancer fulfilled the inclusion criteria. Sixty-one patients (66%) had HM only, 13 (14%) had LM only and 19 patients (20%) had both HM and LM. Forty-six percent of patients had HER2-positive breast cancer, 26% had hormone receptor-positive breast cancer and 28% of patients had a triple negative subtype. After three months of capecitabine treatment intracranial response was 53%. Median OS in the patient group with intracranial response was 16.5 months versus 4.5 months in the non-response group. The hazard ratio (HR) for the median OS, corrected for radiotherapy and concurrently administered, other systemic therapy was 0.33 (95% CI: 0.17-0.67). Median intracranial PFS was 7.3 months in the response group versus 1.4 months in the non-response group (p&lt;0.001).The corrected HR for median intracranial PFS 0.13 (95% CI 0.06-0.27). The HER2-positive subtype group showed the longest median OS (22 months) as compared to the other subtypes (OS in hormone-receptor positive and triple negative subtype both 12 months) Conclusion Fifty-three percent of breast cancer patients with HM and/or LM treated with capecitabine demonstrate an intracranial response after three months of treatment. HER2+ breast cancer patients with HM and/or LM have a longer survival than patients with hormone receptor-positive or triple negative breast cancer subtypes.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noac174.250</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2022-09, Vol.24 (Supplement_2), p.ii72-ii72
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9443387
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central
subjects POSTER PRESENTATIONS
title P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T20%3A49%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P11.61.B%20Capecitabine%20treatment%20of%20CNS%20metastases%20from%20breast%20cancer:%20intracranial%20response%20and%20survival&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Luitse,%20M%20J%20A&rft.date=2022-09-05&rft.volume=24&rft.issue=Supplement_2&rft.spage=ii72&rft.epage=ii72&rft.pages=ii72-ii72&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noac174.250&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noac174.250%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noac174.250&rfr_iscdi=true